Denosumab is a RANKL monoclonal antibody approved for the treatment of postmenopausal OP, age-related OP, and GIOP [112], but also PDB, primary and secondary hyperparathyroidism. The gene discussed is TNFSF11; the disease is secondary hyperparathyroidism.